Humacyte

HUMA

Market cap $179M

Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous trading session.

- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America -

The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change from its previous close.

Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.

Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access Transcript

Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's Vascular Annual Meeting in Boston – – Women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – – Company to hold investor event today, June 15 th , at 5:00 p.m. ET – DURHAM, N.C.

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte's common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.